Brief: Amgen Reports Positive Topline Phase 3 Results For Subcutaneous Tepezza In Thyroid Eye Disease
06/04/2026 14:00
April 6 (Reuters) - Amgen Inc AMGN.O: AMGEN: ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR SUBCUTANEOUS TEPEZZA IN ADULTS WITH MODERATE-TO-SEVERE ACTIVE THYROID EYE DISEASE AMGEN: PHASE 3 TEPEZZA OBI TRIAL MET PRIMARY & KEY SECONDARY ENDPOINTS AMGEN: PHASE 3 TEPEZZA TRIAL OVERALL SAFETY RESULTS GENERALLY CONSISTENT WITH KNOWN SAFETY PROFILE OF TEPEZZA IV AMGEN: PHASE 3 TEPEZZA TRIAL SHOWED CLINICALLY MEANINGFUL REDUCTION IN PROPTOSIS Further company coverage: AMGN.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Amgen
See all newsFactbox: Global drugmakers invest billions to boost US presence
China's Harbour BioMed to focus on another patent case after $20 million damages award
Amgen owes $20.2 million in antibody patent lawsuit, US jury says (updated)
Amgen owes $20.2 mln in antibody patent lawsuit, US jury says
Amgen taps research firm to reassess Tavneos data (updated)